+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating oral Terbinafine, a long-licensed antifungal drug, for patients with biochemical recurrence of prostate cancer after prior local treatments aimed at cure. This phase II drug-repurposing study focuses on men whose cancer has returned biochemically but without visible metastases on imaging. Current standard treatments often involve androgen deprivation or androgen-receptor pathway inhibitors, which can cause significant side effects and quality of life impacts. Terbinafine inhibits the enzyme squalene epoxidase, which may influence prostate cancer progression, and preliminary data suggest it might have anti-cancer effects. Participants will be randomly assigned to receive one of three Terbinafine doses the standard 250 mg, or escalated doses of 500 mg or 1000 mg, taken orally in cycles of 28 days. Stage I includes up to 27 patients 9 per dose level, and based on these results, additional patients will be enrolled in Stage II at a selected dose. Treatment duration in both stages can last up to 12 cycles of 28 days each. During the study, participants will have their prostate-specific antigen PSA levels monitored to assess progression-free rates over 12 weeks and up to one year for progression-free survival and PSA response. Safety and tolerability will also be observed. The study runs from April 2026 to October 2030, with assessments including imaging and blood tests. The study aims to explore Terbinafines activity and optimal dosing for delaying disease progression in this patient group.

Age: 18Years +MALEPhase 2
11 locations